ANRO
ANROHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeANRO operates as a clinical-stage biopharmaceutical company in the United States. At a $1.40B market cap, ANRO ranks as a small-cap company within healthcare. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD).
Market Cap
$1.40B
Beta
1.16
P/E (TTM)
—
P/E (Fwd)
-10.82
EPS (TTM)
$-2.32
EPS (Fwd)
$-3.29
ROE
-49.2%
ROA
-26.8%
Cash
$243.7M
Total Debt
$23.3M
Free CF
-$42.9M
52W Change
813.9%
Annual Financials
Cash vs Debt
Where ANRO stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ANRO finished 52.35% above its 150-day moving average ($24.05) and 66.32% above its 200-day moving average ($22.03). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ANRO overbought or oversold?
At the September 3, 2026 close, ANRO's RSI(14) was 73.8, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
ANRO holds $243.7M in cash against $23.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$42.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -49.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for ANRO and its sector.